AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 21 min read

Grupo Cibest S.A. Stock 12‑Month Price Target Raised to $98.89, Implies 9% Upside

Analysts raised Grupo Cibest S.A.'s 12-month price target to $98.89, up from $96.21, with a range of $71 to $122.1. This implies a 9% upside from the Oct. 1 closing price. The consensus rating remains 'Hold' with 2 Buys, 5 Holds, and 1 Sell.

Original reporting
tradingview.com
Published Oct 2, 2026, 10:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 10:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Grupo Cibest S.A. Stock 12‑Month Price Target Raised to $98.89, Implies 9% Upside — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

The modest upward revision suggests slight bullish sentiment but limited actionable insight.

02

Market read

Minor analyst target update with limited market impact.

03

What to watch

Lack of recent earnings or operational updates limits confidence in the new target.

Relevance 5/10Novelty 4/10Timing: today

Background

Analyst consensus raised the 12‑month price target for Grupo Cibest S.A. from $96.21 to $98.89.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Target raise may be overly optimistic given limited company visibility.

Key entities

  • Company
    Grupo Cibest S.A.

    Subject of the price target revision.

Read at source← All news

Related articles

AUG 10
$CIBHigh

Grupo Cibest S.A. (CIB): Financial results for Q2 2026

Grupo Cibest S.A. (CIB) furnished an SEC Form 6-K — earnings release. 2Q26 GRUPO CIBEST (NYSE: CIB; BVC: CIBEST AND PFCIBEST) REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026. • On June 30, 2026, Grupo Cibest finalized the sale of Banistmo S.A., initially announced to the market on December 18, 2025. As a result of the sale, Grupo Cibest tr

SEC EDGAR 6-K2 min
JUL 21
$CIBMedAI 8/10

CIB 2Q26 Earnings Release

Commercial International Bank (CIB) reported 1H26 consolidated revenue of EGP 65.6bn and net profit of EGP 39.3bn. 2Q26 net profit was EGP 21.5bn. The bank reported gross loans of EGP 680bn, deposits of EGP 1.30tn, NPLs-to-gross loans of 1.49%, and Tier capital of EGP 257bn (28.4% of RWA).

investegate.co.uk6 min
MAY 26
$ECMed

Colombia Stock Market Jumps 2.4% as Oil Eases Before Vote

Colombia’s MSCI COLCAP rose 2.37% to 2,132.79 on Monday (May 25), its biggest gain in weeks, after the index was at cycle-low oversold levels and oil prices eased. The report says Brent fell below $100 following Iran-related “framework” relief, lifting regional risk sentiment. With Colombia’s May 31 presidential first round six days away and a poll blackout active, BanRep was unchanged at 11.25%.

riotimesonline.com4 min
OCT 2
$BMRNMed

BioMarin Announces Five-Year Phase 3 Data for POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at World Muscle Society Annual Congress

BioMarin (BMRN) presented five-year data for POMBILITI + OPFOLDA in late-onset Pompe disease at the World Muscle Society Congress. The study showed durable motor function and pulmonary stabilization. No new safety signals were identified. Additionally, BioMarin shared positive Phase 1/2 data for nivudirsen (BMN 351) in Duchenne muscular dystrophy, showing favorable tolerability and positive dystrophin expression.

prnewswire.com2 min